Emactuzumab

A monoclonal antibody used in cancer treatment

Emactuzumab
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Emactuzumab is a monoclonal antibody designed for the treatment of certain types of cancer. It specifically targets the colony-stimulating factor 1 receptor (CSF1R), which is involved in the regulation of macrophage activity. By inhibiting this receptor, Emactuzumab can modulate the tumor microenvironment, potentially reducing tumor growth and metastasis.

Mechanism of Action

Emactuzumab binds to the CSF1R, a receptor found on the surface of macrophages and other cells of the immune system. CSF1R is a key regulator of macrophage proliferation and survival. By blocking this receptor, Emactuzumab reduces the number of tumor-associated macrophages (TAMs), which are often involved in promoting tumor growth and suppressing anti-tumor immune responses.

Clinical Applications

Emactuzumab is primarily investigated for its use in treating solid tumors, particularly those that are characterized by a high infiltration of TAMs. It has shown promise in early clinical trials for conditions such as tenosynovial giant cell tumor (TGCT), a rare and locally aggressive tumor.

Administration and Dosage

Emactuzumab is administered via intravenous infusion. The dosage and frequency of administration depend on the specific clinical protocol and the condition being treated. Patients receiving Emactuzumab are monitored for potential side effects, including infusion-related reactions and changes in blood cell counts.

Side Effects

Common side effects of Emactuzumab include fatigue, nausea, and edema. More serious adverse effects can include cytopenias, liver enzyme abnormalities, and infusion-related reactions. Patients are closely monitored during treatment to manage these potential side effects.

Research and Development

Emactuzumab is currently under investigation in various clinical trials to assess its efficacy and safety in different cancer types. Research is ongoing to better understand its role in modulating the tumor microenvironment and its potential combination with other immunotherapies.

Related pages

• Monoclonal antibody therapy
• Cancer immunotherapy
• Colony-stimulating factor 1 receptor

• 

  Emactuzumab